Search
Vorinostat
go.drugbank.com/drugs/DB02546ApprovedInvestigationalA recent study suggested that vorinostat also possesses some activity against recurrent glioblastoma multiforme, resulting in a median overall survival of 5.7 months (compared to 4 - 4.4 months in earlier … It is the first in a new class of agents known as histone deacetylase inhibitors.
Netarsudil
go.drugbank.com/drugs/DB13931ApprovedInvestigationalhumour outflow to act as an inhibitor to the rho kinase and norepinephrine transporters found there as opposed to affecting protaglandin F2-alpha analog like mechanisms in the unconventional uveoscleral … production of aqueous As of December 18, 2017 the FDA approved Aerie Pharmaceutical's Rhopressa (netarsudil ophthalmic solution) 0.02% for the indication of reducing elevated intraocular pressure in
Spironolactone
go.drugbank.com/drugs/DB00421ApprovedInvestigational[A178135, A261025] Spironolactone was developed in 1957, marketed in 1959, and approved by the FDA on January 21, 1960.[A178243]
Mixtures: SPIRO COMP FORTE RAT100/20, SPIRO COMP FORTE RAT100/20Fencamfamin
go.drugbank.com/drugs/DB01463ApprovedIllicitWithdrawnFencamfamin (Glucoenergan, Reactivan) is a stimulant which was developed in the 1960s as an appetite suppressant. … It is especially useful in patients with chronic conditions due to its favourable safety profile.
Toremifene
go.drugbank.com/drugs/DB00539ApprovedInvestigational[A256928] Toremifene possesses tissue-specific actions: it has estrogenic (agonist) activity on the cardiovascular system and on bone tissue and it has weak estrogenic effects on uterine tissue, however … , it also has antiestrogenic (estrogen-antagonist) activity on breast tissue.
Alitretinoin
go.drugbank.com/drugs/DB00523ApprovedAn important regulator of gene expression during growth and development, and in neoplasms. … An excess of tretinoin can be teratogenic. It is used in the treatment of psoriasis; acne vulgaris; and several other skin diseases.
Fosnetupitant
go.drugbank.com/drugs/DB14019ApprovedInvestigationalIn April 2018, the U.S. … Considered one of the most distressing side effects of chemotherapy, nausea and vomiting has an immense impact on the quality of life of patients receiving certain antineoplastic therapies [A32865].
Cobimetinib
go.drugbank.com/drugs/DB05239ApprovedInvestigationalIt has been approved in Switzerland and the US, in combination with vemurafenib for the treatment of patients with unresectable or metastatic BRAF V600 mutation-positive melanoma. … Cobimetinib is an orally active, potent and highly selective small molecule inhibiting mitogen-activated protein kinase kinase 1 (MAP2K1 or MEK1), and central components of the RAS/RAF/MEK/ERK signal transduction
Inosine
go.drugbank.com/drugs/DB04335Approved(Dorland, 28th ed) … It is an intermediate in the degradation of purines and purine nucleosides to uric acid and in pathways of purine salvage. It also occurs in the anticodon of certain transfer RNA molecules.
Trimethaphan
go.drugbank.com/drugs/DB01116ApprovedInvestigationalA nicotinic antagonist that has been used as a ganglionic blocker in hypertension, as an adjunct to anesthesia, and to induce hypotension during surgery.